Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.54 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.54 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.54 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribose (Furanose) SCHEMBL15814845 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL14349491 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL447758 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL16199379 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL24087736 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL23017520 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL109435 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL12878699 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL7618455 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL13135754 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111973617-A | Nucleic acid, pharmaceutical composition and conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2020-11-24 | — | — | CN | claimed |
| CN-111973618-A | Nucleic acid, pharmaceutical composition and siRNA conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2020-11-24 | — | — | CN | claimed |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-17 | — | — | US | claimed |
| WO-2018029685-A1 | COMPOSITIONS AND METHODS FOR TREATING A FEAR MEMORY | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2018-02-15 | — | — | WO | claimed |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-08-27 | — | — | US | claimed |
| EP-2827899-B1 | POLYSACCHARIDE ANTIGEN-GLYCOLIPID CONJUGATE VACCINES | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2015-08-05 | — | — | EP | claimed |
| EP-2827899-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-01-28 | — | — | EP | claimed |
| WO-2013178236-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2013-12-05 | — | — | WO | claimed |
| WO-2013139803-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-09-26 | — | — | WO | claimed |
| WO-2010139692-A2 | ANTIVIRAL TRITERPENE DERIVATIVES | SAVIRA PHARMACEUTICALS GMBH (AT) | 2010-12-09 | — | — | WO | claimed |
| EP-0653439-B1 | Stabilized oligonucleotids and the use thereof | AVENTIS PHARMA GMBH (DE) | 2004-04-28 | — | — | EP | claimed |
| US-20020151512-A1 | G cap-stabilized oligonucleotides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-10-17 | — | — | US | claimed |
| JP-2002523335-A | — | — | 2002-07-30 | — | — | JP | claimed |
| EP-0726274-B1 | G-cap stabilized oligonucleotides | AVENTIS PHARMA GMBH (DE) | 2001-10-10 | — | — | EP | claimed |
| US-20010021772-A1 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-13 | — | — | US | claimed |
| EP-1102842-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | Aventis Pharma Deutschland GmbH (DE) | 2001-05-30 | — | — | EP | claimed |
| WO-2000008140-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-02-17 | — | — | WO | claimed |
| EP-0979869-A1 | Short oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-16 | — | — | EP | claimed |
| EP-0978561-A1 | Antisense oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-09 | — | — | EP | claimed |
| US-6013639-A | MODIFYING END GROUPS; DIAGNOSIS, THERAPY CANCER, RESTENOSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-01-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | STT3B, STT3A, DDOST | LGALS1 176/4885LGALS3 119/4885LGALS9 153/4885 |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | STT3B, STT3A, DDOST | LGALS1 176/4885LGALS3 119/4885LGALS9 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.